SeqLL, Inc. (SQL) News
Filter SQL News Items
SQL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest SQL News From Around the Web
Below are the latest news stories about SEQLL INC that investors may wish to consider to help them evaluate SQL as an investment opportunity.
SEQLL INC. GRANTED SECOND 180-DAY EXTENSION BY NASDAQ REGARDING MINIMUM BID REQUIREMENTSBILLERICA, MA, Dec. 22, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services, announced that on December 20, 2022, the Company received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), granting the Company’s request for a 180-day extension to regain compliance with the Nasdaq’s $1.00 minimum bid price requirement |
Brian Paras joins SeqLL as Chief Business OfficerBILLERICA, Mass., Dec. 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced that Brian Paras has joined the company as Chief Business Officer. “Brian brings 30-plus years of product introduction & commercialization, global sales & marketing leadership, and key industry partnership & strategic alliance building to the company. We excitedly welcome him aboard the SeqLL t |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning! |
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving PremarketGainers Aptevo Therapeutics Inc. (NASDAQ: APVO ) shares rose 104% to $7.00 in pre-market trading. Aptevo Therapeutics said 100% clinical benefit rate was achieved in Phase 1b trial evaluating Apvo436 in combination with venetoclax & azacitidine for venetoclax treatment naïve patients with acute myeloid leukemia, Reuters reported. HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM ) shares rose 38.9% to $0.7499 in pre-market trading after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. Bruush Oral Care Inc. (NASDAQ: BRSH ) shares rose 26% to $0.6110 in pre-market trading. Bruush Oral Care reported closing of $3.0 million private placement. SeqLL Inc. (NASDAQ: SQL ) rose 24.2% to $0.5587 in pre-market trading after jumping 15% on Frida... |
SeqLL Third Quarter 2022 Earnings: US$0.078 loss per share (vs US$0.089 loss in 3Q 2021)SeqLL ( NASDAQ:SQL ) Third Quarter 2022 Results Key Financial Results Net loss: US$925.9k (loss widened by 45% from 3Q... |
SeqLL Provides Third Quarter 2022 Financial ResultsBILLERICA, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services aimed at the development of novel scientific assets and intellectual property, today announced its operating and financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Results and Financial Highlights Our revenues during the three months ended September 30, 2022 were $0 as c |
UPDATE -- SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature BiotechnologyBILLERICA, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology. The paper, entitled: “'Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics,” applied Se |
SeqLL Announces Peer-Reviewed Publication of Novel Single-Molecule Liquid Biopsy Method in Nature BiotechnologyBILLERICA, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology. The paper, entitled: “'Multiplexed, single-molecule, epigenetic analysis of plasma-isolated nucleosomes for cancer diagnostics,” applied Se |
SeqLL to Present at the H.C. Wainwright 24th Annual Global ConferenceBILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will present a corporate overview and be available for virtual 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Conference taking place from September 12-14, 2022. The presentation will be available on demand |
SeqLL Inc. Receives Nasdaq Notification Regarding Minimum Bid RequirementsBILLERICA, Mass., June 24, 2022 (GLOBE NEWSWIRE) -- SeqLL Inc. (NASDAQ: SQL and SQLLW) (“SeqLL” or the “Company”), a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property, announced that on June 21, 2022, the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule |